| Literature DB >> 24454774 |
Li Ju1, Guanglin Zhang2, Xing Zhang3, Zhenyu Jia3, Xiangjing Gao2, Ying Jiang2, Chunlan Yan2, Penelope J Duerksen-Hughes4, Fanqing Frank Chen5, Hongjuan Li6, Xinqiang Zhu7, Jun Yang8.
Abstract
The wide application of multi-walled carbon nanotubes (MWCNT) has raised serious concerns about their safety on human health and the environment. However, the potential harmful effects of MWCNT remain unclear and contradictory. To clarify the potentially toxic effects of MWCNT and to elucidate the associated underlying mechanisms, the effects of MWCNT on human lung adenocarcinoma A549 cells were examined at both the cellular and the protein level. Cytotoxicity and genotoxicity were examined, followed by a proteomic analysis (2-DE coupled with LC-MS/MS) of the cellular response to MWCNT. Our results demonstrate that MWCNT induces cytotoxicity in A549 cells only at relatively high concentrations and longer exposure time. Within a relatively low dosage range (30 µg/ml) and short time period (24 h), MWCNT treatment does not induce significant cytotoxicity, cell cycle changes, apoptosis, or DNA damage. However, at these low doses and times, MWCNT treatment causes significant changes in protein expression. A total of 106 proteins show altered expression at various time points and dosages, and of these, 52 proteins were further identified by MS. Identified proteins are involved in several cellular processes including proliferation, stress, and cellular skeleton organization. In particular, MWCNT treatment causes increases in actin expression. This increase has the potential to contribute to increased migration capacity and may be mediated by reactive oxygen species (ROS).Entities:
Mesh:
Substances:
Year: 2014 PMID: 24454774 PMCID: PMC3891800 DOI: 10.1371/journal.pone.0084974
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1MWCNT induces cytotoxicity in A549 cells at high concentrations and longer exposure time.
A549 cells were seeded into 24-well plates (1×104 cells/well) and treated with MWCNT (0.3, 3, 30 and 300 µg/ml) for 2, 12 and 24 h. Cell viability was determined using the trypan blue exclusion assay.
Figure 2MWCNT causes apoptosis and cell cycle perturbation in A549 cells.
(A) Cells were incubated with 0.3, 3, 30 and 300 µg/ml MWCNT for 24 and 48 h, and then were stained with FITC-conjugated Annexin V and PI. The percentage of early stage apoptotic cells and total apoptotic cells were calculated. (B) Cells were incubated with 30 µg/ml MWCNT for 8, 16, 24, 48 and 72 h, and then were fixed and stained with PI. Cells in G1/G0, S and G2/M phases were counted. * p<0.05, compared with control.
Figure 3MWCNT does not cause genotoxic injury to A549 cells.
(A) Following treatment with MWCNT at 0.3, 3 and 30 µg/ml for 2, 12 and 24 h, cells were fixed and stained with anti-γH2AX antibody, then subjected to immunofluorescent microscopy. Blue, Hoechst3358 stain for nuclei; Green, γH2AX. (B) Cells were treated with MWCNT for 24 h at 0.3, 3 and 30 µg/ml, and then subjected to the comet assay detection. The nucleus was stained with gel-red. 10 µM cisplatin (Pt) treated cells were used as a positive control.
Comet assay results for MWCNT treated A549 cells.
| Control | MWCNT 0.3 µg/ml | MWCNT 3 µg/ml | MWCNT 30 µg/ml | Pt | |
| Tail DNA% | 0.57±0.19 | 0.47±0.13 | 0.63±0.38 | 0.76±0.16 | 17.63±2.13* |
| Tail Moment | 0.29±0.24 | 0.01±0.00 | 0.04±0.03 | 0.08±0.02 | 44.84±8.47* |
After treatment with MWCNT at 0.3, 3 and 30 µg/ml for 24 h, the fluorescent images of A549 cells subjected to the neutral comet assay were captured and analyzed by Image-Pro software. Data are represented as mean ± SD, n = 5, * p<0.05, compared with untreated control.
Figure 4Treatment with MWCNT significantly changes protein expression.
Protein extracts (200 µg) were separated on a pH 3–10, 24 cm IPG strip, followed by 12% SDS-PAGE. Proteins spots were visualized by silver staining. Shown are representative 2-DE proteomic maps of A549 cells treated with MWCNT at the indicated concentrations (a, 0.3; b, 3; c, 30 µg/ml) for various time periods (A, 2 h; B, 12 h; C, 24 h). Arrows indicate the spots identified by MS (↑up-regulated protein, down-regulated protein), and details of the corresponding spots are listed in Table 2. The location (D) and function classification (E) of identified proteins are shown in the pie charts.
Cellular proteins differentially regulated after MWCNT treatment.
| Biological process | Spot No. | Swiss-prot ID | Protein name | Theoretical PI/MW | Function |
| ||
| 2 h | 12 h | 24 h | ||||||
| Cellular process related proteins | 1201 | P04632 | Calpain small subunit 1 | 5.05/28.315.67 | Cell proliferation regulation | −1.70b | ||
| 5801 | Q8WUM4 | Programmed cell death 6-interacting protein | 6.13/96818.34 | Cell apoptosis; Cell cycle regulation | −2.71b −1.88c | |||
| 6402 | P04083 | Annexin A1 | 6.57/38714.23 | T cell differentiation; Anti-apoptosis | −2.33c | |||
| 8110 | Q06830 | Peroxiredoxin-1 | 8.27/22110.34 | Cell proliferation; Redox regulation | +1.68a | |||
| 0619 | P27797 | Calreticulin | 4.29/48141.7 | Calcium-binding chaperone; Cell cycle arrest | +1.92a +2.37b +2.28c | |||
| 2303 (12 h) 1412 (2 h) | P08758 | Annexin A5 | 4.94/35936.83 | Anti-apoptosis; Signal transduction | −2.24c | +1.55b | ||
| 7309 | P45880 | Voltage-dependent anion-selective channel protein 2 | 6.32/38092.61 | Form a channel to negative regulation apoptotic and protein polymerization | +1.89c | |||
| 0306 | P62258 | 14-3-3 protein epsilon | 4.63/29173.98 | G2/M transition of mitotic cell cycle; apoptotic process | −2.26c | |||
| 1006 | P09382 | Galectin-1 | 5.34/14715.69 | Regulate apoptosis, cell proliferation and cell differentiation | +1.77b | |||
| 3204 | P09211 | Glutathione S-transferase P | 5.43/23355.85 | Cell proliferation, Glutathione metabolization | −1.50b | |||
| 7412 | P07355 | Annexin A2 | 7.57/38604.07 | Calcium binding protein, involved in heat-stress response | +2.45b +1.80c | |||
| 4005 | P31949 | Protein S100-A11 | 6.56/11740.42 | Negative regulation of DNA replication and cell proliferation | −2.29c | |||
| 2203 (24 h) 4210 (12 h) | P04792 | Heat-shock protein beta-1 | 5.98/22782.62 | Involved in stress resistance and actin organization | −2.05c | −2.40a −2.10b −1.84c | ||
| 7102 (12 h) 7209 (2 h) | P62826 | GTP-binding nuclear protein Ran | 7.01/24423.06 | Cell cycle; Cell division; Transport | +1.74b | +2.13b +4.40c | ||
| Cell metabolization | 7407 (12 h) 8509 (2 h) | O96008 | Mitochondrial import receptor subunit TOM40 homolog | 6.79/37893.05 | Cellular protein metabolic process | +1.65c | +1.50b | |
| 4305 | Q13011 | Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial | 8.16/35816.13 | Fatty acid metabolism | +1.82a | |||
| 6204 | P47985 | Ubiquinol-cytochrome c reductase iron-sulfur subunit, mitochondrial | 8.55/29652.06 | Respiratory electron transport chain | −1.59a −1.87b −2.0c | |||
| 6301 | P00491 | Purine nucleoside phosphorylas | 6.71/32551.38 | Purine nucleobase metabolic process | −1.87c | |||
| 1109 | Q04760 | Lactoylglutathione lyase | 5.24/20719.67 | Carbohydrate metabolic process; glutathione metabolic process | +1.50c | |||
| 4209 | P30084 | Enoyl-CoA hydratase, mitochondrial | 8.34/31387.37 | Fatty acid beta-oxidation | −1.95a | |||
| 6205 | P18669 | Phosphoglycerate mutase 1 | 6.67/28803.98 | Gluconeogenesis; glycolysis | +1.60b +2.33c | |||
| 6304 | P10768 | S-formylglutathione hydrolase | 6.54/31462.8 | Formaldehyde catabolic process | +1.84a +1.69b +1.82c | |||
| Cell signal transduction | 2315 | O00299 | Chloride intracellular channel protein 1 | 5.09/26922.76 | Form chloride ion channels, involves in signal transduction | +1.56b | ||
| 8106 | P30086 | Phosphatidylethanolamine-binding protein 1 | 7.01/21056.78 | Binds ATP, opioids and phosphatidylethanolamine, as a competitive inhibitor of MEK phosphorylation | +1.50 +2.23c | |||
| 2203 (12 h) | P52565 | Rho GDP-dissociation inhibitor 1 | 5.03/23207.14 | Rho protein signal transduction; Cellular component movement | +1.55b | |||
| 0101 | Q15185 | Prostaglandin E synthase 3 | 4.35/18697.41 | Chaperone cofactor-dependent protein refolding; signal transduction | −1.70b | |||
| Cellular skeleton | 4507 | P60709 | Actin, cytoplasmic 1 | 5.29/41736.77 | Structural constituent of cytoskeleton; ATP binding | +1.50b +2.40c | ||
| 5711 | P26038 | Moesin | 6.08/67820.16 | Structural constituent of cytoskeleton | +1.53a | |||
| 6706 | O75083 | Isoform 1 of WD repeat protein 1 | 6.17/66193.4 | Induces disassembly of actin filaments in conjunction with ADF/cofilin family proteins | −2.49b | |||
| 8009 | P23528 | Cofilin-1 | 8.22/18502.47 | Binds to F-actin, plays a role in the regulation of cell morphology and cytoskeletal organization | +1.69a +1.79c | |||
| 4408 | P40121 | Macrophage capping protein | 5.88/38517.62 | Barbed-end actin filament capping; cell projection assembly | −2.13a −2.57c | |||
| 7008 | P07737 | Profilin-1 | 8.44/15054.14 | Binds to actin and affects the structure of the cytoskeleton | +1.72a +2.27b +1.91c | |||
| 0012 | Q13182 | Myosin regulatory light chain 2, nonsarcomeric | 4.67/19794.13 | Regulation of cell shape | −2.14b | |||
| 1001 (12 h) 0004 (2 h) | P60660 | Myosin light polypeptide 6 | 4.56/16930.02 | Actin-dependent ATPase activity | +1.72c | +2.15c | ||
| 6712 | P35908 | Keratin, type II cytoskeletal 2 epidermal | 8.07/65865.29 | Structural constituent of cytoskeleton | −2.66c | |||
| 1301 | P06753 | Tropomyosin alpha-3 chain | 4.75/29032.82 | Implication in stabilizing cytoskeleton actin filaments | +2.21b | |||
| Proteasome | 6103 | P49721 | Proteasome subunit beta type 2 | 6.52/22836.34 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; G1/S transition of mitotic cell cycle | −1.52a −2.27b | ||
| 3313 | P61289 | Proteasome activator complex subunit 3 | 5.79/30886.69 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; G1/S transition of mitotic cell cycle | +2.22b | |||
| 4004 | P61088 | Ubiquitin-conjugating enzyme E2 N | 6.13/17137.86 | DNA damage; DNA repair; Ubl conjugation pathway | −2.84a | |||
| 0310 | P28066 | Proteasome subunit alpha type-5 | 4.74/26411.05 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; G1/S transition of mitotic cell cycle | +1.51b +1.68c | |||
| 3302 | Q86SZ7 | Proteasome activator subunit 2 | 5.54/27401.69 | Proteasome activator complex | −1.85c | |||
| Others | 5407 | Q15366 | Poly(rC)-binding protein 2 | 6.33/38221.66 | Innate immune response; mRNA splicing via spliceosome | −2.03c | ||
| 3202 (12 h) 3304 (2 h) | P40261 | Nicotinamide N-methyltransferase | 5.56/29574.1 | Catalyzes the N-methylation of nicotinamide and other pyridines to form pyridinium ions | −2.36c | +1.87b +2.35c | ||
| 0405 | Q07021 | Complement component 1 Q subcomponent-binding protein, mitochondrial | 4.74/31362.33 | Involved in inflammation and infection processes, ribosome biogenesis, regulation of apoptosis, transcriptional regulation and pre-mRNA splicing | −2.12b | |||
| 1002 | P61970 | Nuclear transport factor 2 | 5.1/14478.47 | Facilitates protein transport into the nucleus | +1.97b +1.92c | |||
| 0402 | P43307 | Translocon-associated protein subunit alpha | 4.39/32235.45 | Involves in the recycling of the translocation apparatus | +1.51a | |||
+, up-regulated proteins; -, down-regulated proteins; a, 0.3 µg/ml; b, 3 µg/ml; c, 30 µg/ml.
Figure 5MWCNT treatment decreases 14-3-3ε and HSP27 expression.
(A) Enlarged 2-DE images of spot 0306 (left panel) and spot 2203 (right panel), which were down-regulated in MWCNT-treated A549 cells; (B) Western blot results for 14-3-3ε (left panel)/HSP27 (right panel) expression in A549 cells treated with 0.3, 3 and 30 µg/ml for 2 h/24 h; (C) Densitometry analysis of (B). GAPDH was used as a loading control. * p<0.05.
Figure 6MWCNT treatment increases actin expression.
(A) Enlarged 2-DE images of spot 4507, which was up-regulated in MWCNT-treated A549 cells. (B) Western blot results for actin expression in A549 cells treated with 0.3, 3 and 30 µg/ml for 24 h. (C) Densitometry analysis of (B). GAPDH was used as a loading control, * p<0.05. (D) Immunofluorescence microscopic analysis of actin expression after MWCNT treatment. After treatment with MWCNT at 0.3, 3 and 30 µg/ml for 2, 12 and 24 h, cells were fixed and stained with phalloidin, then subjected to immunofluorescence microscopy. Shown are representative images from one of three independent experiments. Blue, Hoechst3358 stain for nuclei. Red, Actin. 10 µM Pt was used as a positive control. (E) Semi-quantification data of the average fluorescent intensity. * p<0.05, compared to control.
Figure 7MWCNT induces the generation of cellular reactive oxygen species (ROS).
(A) Cells were exposed to 0.3, 3 and 30 µg/ml MWCNT for 2, 12 and 24 h, and ROS generation was measured using MitoSOX™ Red mitochondrial superoxide indicator by Immunofluorescence microscopy. (B) Cells were exposed to the indicated concentrations of MWCNT for various times, and ROS generation was measured using 2′,7′-dichlorofluorescin diacetate (DCFH-DA) using a spectrofluorometer. ROS generation was expressed as fold increase of fluorescence compared to the control; * p<0.05, compared to PBS treated control. (C) Cells were pretreated with NAC (10 mM) for 2 h, and then exposed to 30 µg/ml of MWNCT for 24 h. * p<0.05, compared with the control. # p<0.05, compared to MWCNT treatment without NAC pre-incubation.
Figure 8Inhibition of ROS generation attenuates actin expression in MWCNT-treated A549 cells.
After MWCNT treatment, cells were fixed and stained with phalloidin, and then subjected to immunofluorescent microscopy. (A) Control; (B) Cells treated with 30 µg/ml of MWNCT for 24 h; (C) Cells treated with NAC (10 mM, 2 h) followed by 30 µg/ml of MWNCT for 24 h; (D) Quantitative analysis of average fluorescent intensity of the above images. * p<0.05, compared with the control; # p<0.05, compared with MWCNT treatment cells.
Figure 9MWNCT leads to increased cell migration.
A549 cells were grown to confluence, scratched, and allowed to recover for 24(A) Control; (B) 30 µg/ml MWCNT exposure; (C) Cells treated with NAC (10 mM, 2 h) followed by 30 µg/ml of MWNCT for 24 h. Shown were representative images from three independent experiments. Scale bar = 50 µm. (D) The distances of migrating cells were determined and data were presented as mean ± SD. * p<0.05 versus control, # p<0.05 versus MWCNT treated cells.
Figure 10Effects of MWCNT exposure on the expression of Th1/Th2 cytokines.
Following treatment with MWCNT at 0.3, 3 and 30 µg/ml for 2, 12 and 24 h, the supernatants of A549 cells were collected and detected using a Human Th1/Th2 Cytokine Kit II by flow cytometry. Shown are expression levels of IFN-γ, IL-10, IL-4, IL-2 (A) and IL-6 (B).